Human T-bet governs innate and innate-like adaptive IFN-γ immunity against mycobacteria

0 views • Oct 25, 2021
0
Save
Cite
Share

Author(s)

Author Name

Rui Yang

Published 1 Project

Immunology

Federico Mele

Ricercatore

Published 1 Project

Immunology

Lisa Worley

Published 1 Project

Immunology

David Langlais

Assistant Professor, McGill University

Published 1 Project

Immunology

Jérémie Rosain

Published 1 Project

Immunology

Ibithal Benhsaien

Published 1 Project

Immunology

Houda Elarabi

Published 1 Project

Immunology

Carys A. Croft

Published 1 Project

Immunology

Jean-Marc Doisne

Published 1 Project

Immunology

Peng Zhang

Published 2 Projects

Immunology Genetics

Marc Weisshaar

Published 1 Project

Immunology

David Jarrossay

Published 1 Project

Immunology

Daniela Latorre

Published 1 Project

Immunology

Yichao Shen

Baylor College of Medicine

Published 1 Project

Immunology

Jing Han

The Ohio State University

Published 1 Project

Immunology

Conor Gruber

Icahn School of Medicine at Mount Sinai

Published 2 Projects

Immunology SARS-CoV-2 Autoimmunity Covid19 Immune

Janet Markle

Vanderbilt University Medical Center

Published 1 Project

Immunology

Fatima Al Ali

Uploader

Taushif Khan

Yoann Seeleuthner

Published 1 Project

Immunology

Gaspard Kerner

Published 1 Project

Immunology

Lucas T. Husquin

Published 1 Project

Immunology

Julia L. Maclsaac

Published 1 Project

Immunology

Mohamed Jeljeli

Published 1 Project

Immunology

Fatima Ailal

Published 1 Project

Immunology

Michael S Kobor

Published 1 Project

Immunology

Carmen Oleaga-Quintas

Published 1 Project

Immunology

Manon Roynard

Published 1 Project

Immunology

Mathieu Bourgey

Published 1 Project

Immunology

Jamila El Baghdadi

Published 1 Project

Immunology

Stephanie Boisson-Dupuis

Published 1 Project

Immunology

Anne Puel

Published 1 Project

Immunology

Fréderic Batteux

Published 1 Project

Immunology

Flore Rozenberg

Published 1 Project

Immunology

Nico Marr

Add New Author

Inborn errors of human IFN-γ immunity underlie mycobacterial disease. We report a patient with mycobacterial disease due to an inherited deficiency of the transcription factor T-bet. This deficiency abolishes the expression of T-bet target genes, including IFNG , by altering chromatin accessibility and DNA methylation in CD4+ T cells. The patient has profoundly diminished counts of mycobacterial-reactive circulating NK, invariant NKT (iNKT), mucosal-associated invariant T (MAIT), and Vδ2+ γδ T lymphocytes, and of non-mycobacterial-reactive classic TH1 lymphocytes, the remainders of which also produce abnormally low amounts of IFN-γ. Other IFN-γ-producing lymphocyte subsets however develop normally, but with low levels of IFN-γ production, with exception of Vδ2− γδ T lymphocytes, which produce normal amounts of IFN-γ in response to non-mycobacterial stimulation, and non-classic TH1 (TH1*) lymphocytes, which produce IFN-γ normally in response to mycobacterial antigens. Human T-bet deficiency thus underlies mycobacterial disease by preventing the development of, and IFN-γ production by, innate (NK) and innate-like adaptive lymphocytes (iNKT, MAIT, and Vδ2+ γδ T cells), with mycobacterial-specific, IFN-γ-producing, purely adaptive αβ TH1* cells unable to compensate for this deficit. ### Competing Interest Statement Dr. Glimcher serves on the Board of Directors of GlaxoSmithKline Pharmaceutical Company and the Analog Device Corporation and formerly served on the Boards of Bristol Myers Squibb Pharmaceutical Company and the Waters Corporation. She is also on the Scientific Advisory Boards of Abpro, Kaleido, and Repare biotechnology companies. Dr. Casanova serves on the Scientific Advisory Boards of ADMA Biologics Inc., Celgene and Kymera Therapeutics, Inc.. He also consults for Elixiron Immunotherapeutics. Other authors declare no competing interests.

Immunology
Immunology 63 Projects